-- 截至5月1日当周，美国石油产品出口总量达到每日820万桶，创下自美国能源信息署（EIA）1991年2月开始发布该产品出口数据以来的最高纪录。 根据EIA的周度数据，该周度数据高于前一周的770万桶/日。 EIA数据显示，受原油出口大幅下降的影响，美国原油和石油产品总出口量为每日1297万桶，低于前一周的每日1418万桶。 原油出口量为每日480万桶，低于前一周的每日640万桶。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL